Salim Oulghazi

Salim Oulghazi, MD, is a resident in the Department of Hematology/Oncology at Heidelberg University Hospital. He studied medicine in Frankfurt (Goethe University), Sydney (University of Sydney) and Cape Town (Stellenbosch University) with scholarships from the Federal Ministry of Education and Research. While his time in medical school, he studied lymphocyte trafficking in a mouse model of autoimmune diabetes at the Institute of Transfusion Medicine and Immunohematology under the supervision of Prof. Dr. Halvard Bönig. After publishing his findings on VLA-4 as a target for primary prevention in autoimmune diabetes in 2020 he received his Dr. med. (summa cum laude) from Goethe University. In 2022, he joined the Müschen lab at Yale as a postdoctoral fellow of the Dr. Mildred Scheel Cancer Foundation to study negative regulation of Wnt signaling in lymphoid malignancies.